Literature DB >> 29916840

Developments in the treatment of benign essential blepharospasm.

Michael T Yen1.   

Abstract

PURPOSE OF REVIEW: To review new developments in the medical and surgical treatment options for benign essential blepharospasm (BEB). RECENT
FINDINGS: Botulinum toxin injections remain the mainstay treatment for BEB with several formulations currently commercially available. Reports in the medical literature support photochromatic modulation for the symptoms of photophobia, as well as oral medications and surgical myectomy for control of the motor signs of eyelid protractor spasm.
SUMMARY: Although there remains no cure for BEB, several treatment options are available to effectively manage the signs and symptoms of the condition.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29916840     DOI: 10.1097/ICU.0000000000000500

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  5 in total

Review 1.  Vitamin D, the Vitamin D Receptor, Calcitriol Analogues and Their Link with Ocular Diseases.

Authors:  Miłosz Caban; Urszula Lewandowska
Journal:  Nutrients       Date:  2022-06-05       Impact factor: 6.706

2.  Screening Gene Mutations in Chinese Patients With Benign Essential Blepharospasm.

Authors:  Hongjuan Dong; Ying Luo; Shanghua Fan; Bo Yin; Chao Weng; Bin Peng
Journal:  Front Neurol       Date:  2020-01-23       Impact factor: 4.003

3.  Voxel-Wise Brain-Wide Functional Connectivity Abnormalities in Patients with Primary Blepharospasm at Rest.

Authors:  Pan Pan; Shubao Wei; Huabing Li; Yangpan Ou; Feng Liu; Wenyan Jiang; Wenmei Li; Yiwu Lei; Yanqing Tang; Wenbin Guo; Shuguang Luo
Journal:  Neural Plast       Date:  2021-01-06       Impact factor: 3.599

4.  Impaired Topographic Organization in Patients With Idiopathic Blepharospasm.

Authors:  Yanbing Hou; Lingyu Zhang; Qianqian Wei; Ruwei Ou; Jing Yang; Qiyong Gong; Huifang Shang
Journal:  Front Neurol       Date:  2022-01-12       Impact factor: 4.003

5.  Ultra-Long-Term Therapy of Benign Essential Blepharospasm with Botulinumtoxin A-30 Years of Experience in a Tertiary Care Center.

Authors:  Bettina Wabbels; Rolf Fimmers; Peter Roggenkämper
Journal:  Toxins (Basel)       Date:  2022-02-07       Impact factor: 4.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.